[go: up one dir, main page]

RU2015114540A - PARTICLES OF LEFG-FUSION DERIVATIVE PROPIONIC ACID FOR USE IN ORAL DOSED FORMS - Google Patents

PARTICLES OF LEFG-FUSION DERIVATIVE PROPIONIC ACID FOR USE IN ORAL DOSED FORMS Download PDF

Info

Publication number
RU2015114540A
RU2015114540A RU2015114540A RU2015114540A RU2015114540A RU 2015114540 A RU2015114540 A RU 2015114540A RU 2015114540 A RU2015114540 A RU 2015114540A RU 2015114540 A RU2015114540 A RU 2015114540A RU 2015114540 A RU2015114540 A RU 2015114540A
Authority
RU
Russia
Prior art keywords
propionic acid
particles
wax
derivative
acid derivative
Prior art date
Application number
RU2015114540A
Other languages
Russian (ru)
Inventor
Саумитра БАГЧИ
Мурали К. ВУППАЛА
Original Assignee
МакНЕЙЛ-ППС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/789,797 external-priority patent/US20140256810A1/en
Application filed by МакНЕЙЛ-ППС, ИНК. filed Critical МакНЕЙЛ-ППС, ИНК.
Publication of RU2015114540A publication Critical patent/RU2015114540A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

1. Способ производства частиц производного пропионовой кислоты, включающий:плавление производного пропионовой кислоты и воска при перемешивании;диспергирование расплавленной смеси производного пропионовой кислоты/воска в горячей воде;перенос горячей дисперсии производного пропионовой кислоты/воска/горячей воды в другой контейнер, содержащий холодную воду, где диспергированные капли смеси производного пропионовой кислоты/воска застывают и образуют мелкодисперсные/сферические частицы; ифильтрование и сушку мелкодисперсных/сферических частиц.2. Способ по п. 1, в котором указанное производное пропионовой кислоты выбрано из группы, состоящей из ибупрофена, напроксена, беноксапрофена, напроксена натрия, флурбипрофена, фенопрофена, фенбупрофена, кетопрофена, индопрофена, пирпрофена, карпофена, оксапрофена, пранопрофена, микропрофена, тиоксапрофена, супропрофена, алминопрофена, тиапрофеновой кислоты, флупрофена и буклоксовой кислоты.3. Способ по п. 1, в котором указанный воск представляет собой глицерилбегенат.4. Способ производства дозированной формы, включающий:смешивание частиц производного пропионовой кислоты по п. 1 с эксципиентами дозированной формы; ипрессование смеси в дозированную форму.5. Частицы производного пропионовой кислоты, приготовленные способом по п. 1.6. Дозированная форма, приготовленная способом по п. 2.7. Способ лечения, включающий введение дозированной формы по п. 6.8. Фармацевтический состав с быстрым высвобождением, содержащий частицы производного пропионовой кислоты по п. 5.9. Фармацевтический состав с быстрым высвобождением по п. 8, причем указанный состав представляет собой жевательную таблетку.10.1. A method of manufacturing particles of a propionic acid derivative, comprising: melting a propionic acid derivative and wax with stirring; dispersing a molten propionic acid derivative / wax mixture in hot water; transferring the hot dispersion of the propionic acid derivative / wax / hot water to another container containing cold water where dispersed drops of a propionic acid / wax derivative mixture solidify and form finely divided / spherical particles; filtering and drying fine / spherical particles. 2. The method of claim 1, wherein said propionic acid derivative is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, naproxen sodium, flurbiprofen, phenoprofen, fenbuprofen, ketoprofen, indoprofen, pirprofen, carpofen, oxaprofen, microprofenoprofenofenoprofenofenoprofenofenoprofenofenoprofenoprofenoprofenofenoprofenoprofenoprofenoprofenoprofenoprofenoprofenoprofen fenrofenoprofen fenrofenoprofen. , alminoprofen, thiaprofenic acid, fluprofen and bucloxic acid. 3. The method of claim 1, wherein said wax is glyceryl behenate. A method of manufacturing a dosage form, comprising: mixing particles of a derivative of propionic acid according to claim 1 with excipients of the dosage form; pressing the mixture into a dosage form. 5. Particles of the propionic acid derivative prepared by the method of claim 1.6. The dosage form prepared by the method according to p. 2.7. A method of treatment comprising administering a dosage form according to claim 6.8. A rapid release pharmaceutical composition comprising particles of a propionic acid derivative according to claim 5.9. The pharmaceutical composition with rapid release according to claim 8, wherein said composition is a chewable tablet.

Claims (12)

1. Способ производства частиц производного пропионовой кислоты, включающий:1. A method of manufacturing particles of a derivative of propionic acid, including: плавление производного пропионовой кислоты и воска при перемешивании;melting the propionic acid derivative and the wax with stirring; диспергирование расплавленной смеси производного пропионовой кислоты/воска в горячей воде;dispersing a molten propionic acid / wax derivative mixture in hot water; перенос горячей дисперсии производного пропионовой кислоты/воска/горячей воды в другой контейнер, содержащий холодную воду, где диспергированные капли смеси производного пропионовой кислоты/воска застывают и образуют мелкодисперсные/сферические частицы; иtransferring the hot dispersion of the propionic acid derivative / wax / hot water to another container containing cold water, where the dispersed drops of the propionic acid / wax derivative mixture solidify and form finely divided / spherical particles; and фильтрование и сушку мелкодисперсных/сферических частиц.filtering and drying fine / spherical particles. 2. Способ по п. 1, в котором указанное производное пропионовой кислоты выбрано из группы, состоящей из ибупрофена, напроксена, беноксапрофена, напроксена натрия, флурбипрофена, фенопрофена, фенбупрофена, кетопрофена, индопрофена, пирпрофена, карпофена, оксапрофена, пранопрофена, микропрофена, тиоксапрофена, супропрофена, алминопрофена, тиапрофеновой кислоты, флупрофена и буклоксовой кислоты.2. A method according to Claim. 1, wherein said propionic acid derivative is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, naproxen sodium, flurbiprofen, fenoprofen, fenbuprofena, ketoprofen, indoprofen, pirprofen, karpofena, oksaprofena, pranoprofen, microprofiles, tioxaprofen suproprofen, alminoprofen, thiaprofenic acid, fluprofen and bucloxic acid. 3. Способ по п. 1, в котором указанный воск представляет собой глицерилбегенат.3. The method of claim 1, wherein said wax is glyceryl behenate. 4. Способ производства дозированной формы, включающий:4. A method of manufacturing a dosage form, including: смешивание частиц производного пропионовой кислоты по п. 1 с эксципиентами дозированной формы; иmixing particles of a propionic acid derivative according to claim 1 with dosage form excipients; and прессование смеси в дозированную форму.pressing the mixture into a dosage form. 5. Частицы производного пропионовой кислоты, приготовленные способом по п. 1.5. Particles of a derivative of propionic acid prepared by the method of claim 1. 6. Дозированная форма, приготовленная способом по п. 2.6. The dosage form prepared by the method according to p. 2. 7. Способ лечения, включающий введение дозированной формы по п. 6.7. A method of treatment comprising administering a dosage form according to claim 6. 8. Фармацевтический состав с быстрым высвобождением, содержащий частицы производного пропионовой кислоты по п. 5.8. The pharmaceutical composition with a quick release containing particles of a derivative of propionic acid according to claim 5. 9. Фармацевтический состав с быстрым высвобождением по п. 8, причем указанный состав представляет собой жевательную таблетку.9. The pharmaceutical composition with a quick release according to claim 8, wherein said composition is a chewable tablet. 10. Фармацевтический состав с быстрым высвобождением по п. 8, причем указанный состав представляет собой таблетку для рассасывания в полости рта.10. The pharmaceutical composition with a quick release according to claim 8, wherein said composition is a tablet for absorption in the oral cavity. 11. Фармацевтический состав с быстрым высвобождением по п. 8, в котором указанные частицы производного пропионовой кислоты содержат от приблизительно 80 частей производного пропионовой кислоты/приблизительно 20 частей воска до приблизительно 95 частей производного пропионовой кислоты/приблизительно 5 частей воска.11. The rapid release pharmaceutical composition of claim 8, wherein said particles of a propionic acid derivative comprise from about 80 parts of a propionic acid derivative / about 20 parts of a wax to about 95 parts of a propionic acid derivative / about 5 parts of a wax. 12. Фармацевтический состав с быстрым высвобождением по п. 9, в котором указанные частицы производного пропионовой кислоты содержат приблизительно 85 частей производного пропионовой кислоты/приблизительно 15 частей воска. 12. The rapid release pharmaceutical composition of claim 9, wherein said particles of the propionic acid derivative comprise about 85 parts of the propionic acid derivative / about 15 parts of the wax.
RU2015114540A 2012-09-18 2013-09-16 PARTICLES OF LEFG-FUSION DERIVATIVE PROPIONIC ACID FOR USE IN ORAL DOSED FORMS RU2015114540A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261702392P 2012-09-18 2012-09-18
US61/702,392 2012-09-18
US13/789,797 US20140256810A1 (en) 2013-03-08 2013-03-08 Low melting propionic acid derivative particles for use in oral dosage forms
US13/789,797 2013-03-08
PCT/US2013/059918 WO2014047001A1 (en) 2012-09-18 2013-09-16 Low melting propionic acid derivative particles for use in oral dosage forms

Publications (1)

Publication Number Publication Date
RU2015114540A true RU2015114540A (en) 2016-11-10

Family

ID=49231643

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015114540A RU2015114540A (en) 2012-09-18 2013-09-16 PARTICLES OF LEFG-FUSION DERIVATIVE PROPIONIC ACID FOR USE IN ORAL DOSED FORMS

Country Status (8)

Country Link
EP (1) EP2897584A1 (en)
CN (1) CN104640537A (en)
AU (1) AU2013318356A1 (en)
BR (1) BR112015005876A2 (en)
CA (1) CA2884119A1 (en)
HK (2) HK1209372A1 (en)
RU (1) RU2015114540A (en)
WO (1) WO2014047001A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015110511A (en) * 2014-03-28 2016-10-20 МакНЕЙЛ-ППС, ИНК. PARTICULAR DERIVATIVE ACID PARTICLES FOR DIRECT PRESS
CN109956860B (en) * 2019-03-08 2022-03-01 天津大学 A kind of preparation method of ibuprofen spherical crystal
CN116211807B (en) * 2019-11-25 2025-08-08 上海博志研新药物研究有限公司 Ibuprofen pharmaceutical composition, preparation method and application

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
DE3440288C2 (en) 1984-11-05 1987-03-12 Gergely, Gerhard, Dr.-Ing., Wien Pharmaceutical preparation containing ibuprofen and process for its preparation
US4923898A (en) 1984-12-26 1990-05-08 Analgesic Associates Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same
US4873231A (en) 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
CA2063141C (en) 1989-08-04 1997-03-04 Edward J. Roche Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
IT1246383B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR MASKING THE TASTE OF DRUGS
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
WO1994005260A1 (en) 1992-09-03 1994-03-17 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
IT1264855B1 (en) 1993-06-21 1996-10-17 Zambon Spa PHARMACEUTICAL COMPOSITIONS CONTAINING S (+) - 2- (4-ISOBUTYLPHENYL) PROPIONIC ACID SALTS WITH BASIC AMINO ACIDS
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
TW442287B (en) 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
FR2811912B1 (en) 2000-07-21 2003-02-07 Gattefosse Ets Sa PROCESS FOR COATING SOLID PARTICLES WITH A HEAT-MELTING AGENT, AND SOLID PARTICLES THUS COATED
GB0113841D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
JP2007516259A (en) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー Method for preparing mixed phase co-crystal with activator
AU2004325469B2 (en) * 2004-12-10 2009-02-05 Council Of Scientific And Industrial Research Pharmaceutical composition for improving palatability of drugs and process for preparation thereof
WO2008052033A2 (en) 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition

Also Published As

Publication number Publication date
CN104640537A (en) 2015-05-20
EP2897584A1 (en) 2015-07-29
AU2013318356A1 (en) 2015-03-19
HK1212886A1 (en) 2016-06-24
BR112015005876A2 (en) 2017-07-04
WO2014047001A1 (en) 2014-03-27
CA2884119A1 (en) 2014-03-27
HK1209372A1 (en) 2016-04-01

Similar Documents

Publication Publication Date Title
ES2655614T3 (en) Nanostructured compositions of aprepitant, procedure for their preparation and pharmaceutical compositions containing them
Xiao et al. Cocrystals of propylthiouracil and nutraceuticals toward sustained-release: Design, structure analysis, and solid-state characterization
RU2015114540A (en) PARTICLES OF LEFG-FUSION DERIVATIVE PROPIONIC ACID FOR USE IN ORAL DOSED FORMS
BR112012019501A2 (en) procedure for the preparation of carbon black pellets.
SK13652003A3 (en) Potentiation of therapeutic effects of fatty acids
RU2015128794A (en) COMPOSITION OF ORAL DECOMPOSABLE TABLETS, ENSURING INCREASED BIOAVAILABILITY
Wu et al. 131I-labeled silk fibroin microspheres for radioembolic therapy of rat hepatocellular carcinoma
JP2011173892A5 (en)
JP2022538214A (en) Oral solid tablet containing Bruton's tyrosine kinase inhibitor and method for preparing same
CN102248622B (en) Capsule mold release agent and preparation method thereof
CN103463126A (en) Calcium carbonate D3 granula and preparation method thereof
Ullah et al. Moisture-activated dry granulation
Perioli et al. Effects of hydrotalcite-like nanostructured compounds on biopharmaceutical properties and release of BCS class II drugs: The case of flurbiprofen
RU2007135735A (en) SOLID COSMETIC AND THERAPEUTIC COMPOSITIONS SUITABLE FOR APPLICATION ON HUMAN SKIN AND ARE ABLE TO FORM A GEL IN CONTACT WITH WATER
JP2015510935A5 (en)
EA201401266A1 (en) PHARMACEUTICAL COMPOSITION, WHICH CONTAINS (1R, 4R) -6'-Fluoro-N, N-Dimethyl-4-phenyl-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOGEXAN-1,1'-PIRANO- [ 3,4, B] INDOL] -4-AMINE AND DERIVATIVE PROPIONIC ACID
RU2015110511A (en) PARTICULAR DERIVATIVE ACID PARTICLES FOR DIRECT PRESS
Zhai et al. Gastroretentive extended-release floating granules prepared using a novel fluidized hot melt granulation (FHMG) technique
JP2011251959A5 (en)
RU2015114433A (en) ORAL DOSED FORMS WITH SLOW-RELEASE EXTRACTION CONTAINING PARTICLES OF EASY-MELTING DERIVATIVE PROPIONIC ACID
CN102526080A (en) Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof
RU2015131034A (en) SUSTAINABLE COMPOSITION CONTAINING FINGOLIMOD
CN105434375A (en) Levetiracetam tablet and preparation method thereof
CN102641303B (en) Method for preventing roller-bonding phenomenon of material during traditional Chinese medicine dry granulation process
RU2015114437A (en) PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SUSPENSION CONTAINING PARTICLES OF EASY-FUEL DERIVATIVE PROPIONIC ACID

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180119